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SUMMARY
Combined deficiency of vitamin K–dependent clotting factors II, VII, IX, and X (and proteins C,
S, and Z) is usually an acquired clinical problem, often resulting from liver disease,
malabsorption, or warfarin overdose. A rare inherited form of defective γ-carboxylation resulting
in early onset of bleeding was first described by McMillan and Roberts in 1966 and subsequently
has been termed vitamin K–dependent clotting factor deficiency (VKCFD). Biochemical and
molecular studies identify 2 variants of this autosomal recessive disorder: VKCFD1, which is
associated with point mutations in the γ-glutamylcarboxylase gene (GGCX), and VKCFD2, which
results from point mutations in the vitamin K epoxide reductase gene (VKOR). Bleeding ranges in
severity from mild to severe. Therapy includes high oral doses of vitamin K for prophylaxis,
usually resulting in partial correction of factor deficiency, and episodic use of plasma infusions.
Recent molecular studies have the potential to further our understanding of vitamin K metabolism,
γ-carboxylation, and the functional role this posttranslational modification has for other proteins.
The results may also provide potential targets for molecular therapeutics and pharmacogenetics.
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INTRODUCTION
Vitamin K–dependent clotting factor deficiency (VKCFD) is a rare autosomal recessive
bleeding disorder that often presents with severe hemorrhage during infancy. The first case
of VKCFD was reported in 1966 and described a 3-month-old girl with multiple bruises and
hemorrhages [1]. She had no evidence of malabsorption, liver disease, or warfarin
poisoning. She was found to have a prothrombin time of 95 seconds and a partial
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thromboplastin time of 305 seconds. These times corrected on mixing 1:1 with normal
plasma, indicating factor deficiency rather than inhibition of coagulation. Her plasma
showed less than 3% activity of factors II, VII, IX, and X.
The proband was further studied at the age of 15 years and found to have immunologically
recognizable coagulation factors II, VII, IX, and X that lacked γ-carboxyglutamic acid
residues [2]. Both parents of the children were found to have reduced levels of γ-
carboxylated proteins in their urine, suggesting heterozygous defects in the vitamin K
metabolic pathway (H.R. Roberts, personal communication). The roband’s obstetric care at
the age of 34 years was also reported [3]; management continued to involve high doses of
oral vitamin K and plasma infusions for surgical procedures and significant hemorrhages.
Additional VKCFD cases and pedigrees were reported over the years; bleeding has ranged
from mild to severe [4–10].
Subsequent characterization of anticoagulant proteins C, S, and Z in VKCFD cases showed
defective γ-carboxylation of these proteins as well, and a modest propensity to thrombotic
events has been suggested by a few cases [8]. Skeletal defects have also been reported in
some cases, likely due to defective γ-carboxylation of certain bone matrix proteins [7,9,10]
or from vitamin K interactions with other target genes in osteoblasts [11].
The isolation and characterization of the human genes encoding the γ-glutamyl carboxylase
(GGCX) in 1991 by forward genetics [12,13] and the vitamin K epoxide reductase (VKOR)
in 2004 by reverse genetics and expression cloning [14–16] greatly advanced our
understanding of VKCFD, as well as the metabolism of vitamin K and the biological roles
of γ-carboxylation. Subsequent pedigree studies have looked at missense mutations in each
gene, resulting in the subtype designations VKCFD1 and VKCFD2 [17,18]. Common single
nucleotide polymorphisms (SNPs) in these genes (particularly VKOR) and CYP2C9
(cytochrome p450 2C9) have been examined in large populations of various ethnic
backgrounds in relation to warfarin dosing [reviewed in 19]. Recent work has also focused
on drug development and potential molecular therapeutics using the knowledge gained by
VKCFD, making this rare coagulation disorder relevant in new ways.
METHODS
All current publications in PubMed and other scientific databases were searched.
Approximately 300 articles pertaining to the subject were reviewed in detail. Original
studies published in the past 3 years were chosen for additional analysis. Polymorphisms in
GGCX and VKOR were reviewed in standard genome databases and registries. Selected
investigators working in this area were also contacted. Several recent reviews and
perspectives are also recommended [20–24].
INCIDENCE, RACIAL AND ETHNIC PREDILECTION
VKCFD1 and VKCFD2 are extremely rare autosomal recessive disorders with fewer than
30 cases reported. Carrier incidence, racial distribution, and ethnic predilections are not
known. Cases and pedigrees have been reported in Africa, Asia, Europe, and North
America. As mentioned previously (19), SNP frequencies in the GGCX and VKOR genes in
several large population-based studies have been reported, but obviously these rarely result
in the clinical syndrome VKCFD.
PATHOPHYSIOLOGY
Glutamate residues in coagulation factors II, VII, IX, and X (and the anticoagulant factors
proteins C, S, and Z) are carboxylated by GGCX into γ-carboxyglutamate residues. Nine to
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13 of these residues are found in the amino-terminal region of the circulating form of each
of these proteins, constituting the γ-carboxyglutamic acid-rich Gla domain. Full activity of
these factors (but not immunologic recognition) is provided by this posttranslational
modification of the proteins in the endoplasmic reticulum. Once carboxylated, the proteins
have a calcium-dependent conformation that allows binding to phospholipids and/or
endothelial cells.
Vitamin K in reduced form is required as a cofactor by GGCX during the catalytic reaction:
Glutamic acid -----------------> γ-carboxyglutamic acid
GGCX
Cofactor = Vitamin K reduced
Once vitamin K is oxidized to the epoxide form in this reaction, the reduced form of vitamin
K must be regenerated by the vitamin K epoxide reductase (VKOR):
Vitamin K epoxide------------> Vitamin K reduced
VKOR
The primary target for warfarin’s action is VKOR, resulting in lower levels of the reduced
form of vitamin K. This in turn leads to failure of carboxylation and therefore to decreased
function of coagulation factors in patients treated with coumarin derivatives. Detailed
review of the vitamin K cycle and carboxylation can be found in several recent reviews [20–
22].
GENETICS AND MOLECULAR BASIS
These rare autosomal disorders arise from point mutations in either the GGCX or VKOR
genes. Several compound heterozygous cases and pedigrees have been described [5,7,15].
Carriers are asymptomatic. As Ginsberg notes [23], the rarity of VKCFD and the fact that
only missense mutations have been identified suggest embryonic lethality with complete
deficiency of either enzyme in humans; this is supported by knockout mice results [23].
CLINICAL MANIFESTATIONS
The first case of VKCFD was described in an infant with multiple bruises and hemorrhages,
and subsequent case reports are often similar. VKCFD may present with intracranial
hemorrhage in the neonate or early in life, similar to hemorrhagic disease of the newborn
resulting from acquired vitamin K deficiency [8,14]. A few patients have dysmorphic
features vaguely resembling warfarin embryopathy, but this is a heterogeneous group. Some
of the described patients have also had developmental abnormalities and/or skeletal defects
[7,9,10], and there appears to be a high incidence of fetal wastage [7,9–11,25], although the
small numbers preclude a definitive statement. Milder cases with later onset of diagnosis
have also been reported [5,6]. The most detailed clinical descriptions, however, are found in
the original case report [1], with published followup reports many years later [2,3].
VKCFD patients have markedly prolonged prothrombin time and activated partial
thromboplastin time results that correct with plasma mix. Factors II, VII, IX, and X activity
levels show variably reduced values (though usually quite low) that partially improve with
vitamin K treatment of the patient. Proteins increased in vitamin K’s absence (PIVKA-II;
undercarboxylated prothrombin) are increased, even following therapeutic correction with
plasma infusion. Although the PIVKA-II immunoassay is more sensitive than vitamin K–
dependent factor activity levels, its limited specificity does not allow differentiation of
VKCFD from some forms of liver disease or other disorders resulting in vitamin K
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deficiency. Proteins C, S, and Z activities are also reduced; however, the propensity to
thrombotic events seems to be much less common [8]. This is primarily a bleeding diathesis,
not a thrombophilic disorder.
DIAGNOSIS
Diagnosis of vitamin K deficiency rests on the persistence of bleeding manifestations and
reduced levels of vitamin K–dependent coagulation and anticoagulation factors. Warfarin
ingestion, malabsorption, and liver disease must be ruled out [2]. Reduced vitamin K levels
due to antibiotic therapy can also lead to bleeding in VKCFD patients, and additional
treatment and monitoring may be indicated during infection.
Genotyping for VKORC (5 kb) and GGCX (13 kb) is possible in several research
laboratories [12–16] and should be strongly considered rather than allowing the patient to
have multiple and/or severe bleeding episodes while not taking vitamin K. Point mutations
have also greatly contributed to our understanding of both GGCX and VKOR structure and
function [26–28].
MANAGEMENT
Administration of large doses of oral vitamin k (for example, 15 mg daily in adults) may
partially correct the low factor assay results in severely affected patients to about 15–20%
but may not prevent significant bleeding [2–4]. These partially corrected factor activities
approach the levels seen in milder cases of VKCFD [5,6]. In fact, massive parenteral doses
of vitamin k do not always correct factor II, VII, IX and X activities, and there is clear
biochemical evidence that the molecules are not fully carboxylated by such treatment [2,7].
Continued daily treatment with high dose oral vitamin k is, however, successful in
preventing some bleeding complications [2–8] and is generally recommended for these
patients.
Plasma infusions for surgical procedures and overt hemorrhage are indicated, and VKCFD
patients often require multiple doses. Alternatively, so-called 4-factor prothrombin complex
concentrates (PCCs), which contain factors II, VII, IX, and X and proteins C and S in
variable amounts [29] could be considered. Although these concentrates have rarely been
used in VKCFD in the published literature [7], they have been used effectively in reversing
warfarin anticoagulation and offer a therapeutic option that includes pathogen-inactivation
steps and lower risk of volume overload with repeated dosing when compared with plasma.
PROGNOSIS
Prenatal diagnosis is possible if both alleles are sequenced and familial SNPs are defined.
Prognosis of VKCFD can be guarded based on the propensity for perinatal intracranial
hemorrhage, which can result in permanent neurological damage and developmental
disabilities [8]. Other cases, however, have been milder and have favorable outcomes over
time. Early intervention with appropriate treatment and prevention modalities would likely
improve the prognosis, as with any coagulation disorder. As noted previously, factor levels
partially improve with vitamin K therapy, and regular vitamin K dosing may maintain
hemostasis, though not preventing all complications.
CONCLUSIONS
Future areas of potential clinical relevance resulting from this work include prediction of
warfarin dose using SNPs in VKOR and other genes, design of new small molecule
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inhibitors of VKOR and GGCX, and further definition of defective carboxylation of
nonhematologic proteins.
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